Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
J Vasc Surg. 2011 May;53(5):1178-83. doi: 10.1016/j.jvs.2010.11.045. Epub 2011 Jan 26.
Sac regression is a surrogate marker for clinical success in endovascular aneurysm repair (EVAR) and has been shown to be device-specific. The low porosity Excluder endograft (Excluder low-permeability endoprosthesis [ELPE]; W. L. Gore & Associates Inc, Flagstaff, Ariz) introduced in 2004 was reported in early follow-up to be associated with sac regression rates similar to other endografts, unlike the original Excluder which suffered from sac growth secondary to fluid accumulation in the sac. The purpose of this study was to determine whether this behavior is durable in mid-term to long-term follow-up.
Between July 2004 and December 2007, 301 patients underwent EVAR of an abdominal aortic aneurysm (AAA) with the ELPE at two institutions. Baseline sac size was measured by computed tomography (CT) scan at 1 month after repair. Follow-up beyond 1 year was either with a CT or ultrasound scan. Changes in sac size ≥5 mm from baseline were determined to be significant. Endoleak history was assessed with respect to sac behavior using χ(2) and logistic regression analysis.
Two hundred sixteen patients (mean age 73.6 years and 76% men) had at least 1-year follow-up imaging available for analysis. Mean follow-up was 2.6 years (range, 1-5 years). The average minor-axis diameter was 52 mm at baseline. The proportion of patients with sac regression was similar during the study period: 58%, 66%, 60%, 59%, and 63% at 1 to 5 years, respectively. The proportion of patients with sac growth increased over time to 14.8% at 4-year follow-up. The probability of freedom from sac growth at 4 years was 82.4%. Eighty patients (37.7%) had an endoleak detected at some time during follow-up with 29.6% (16 of 54) residual endoleak rate at 4 years; 13 of the residual 16 endoleaks were type II. All patients with sac growth had endoleaks at some time during the study compared with only 18% of patients with sac regression (P < .0001).
A sustained sac regression after AAA exclusion with ELPE is noted up to 5-year follow-up. Sac enlargement was observed only in the setting of a current or previous endoleak, with no cases of suspected hygroma formation noted.
在血管内动脉瘤修复术(EVAR)中,瘤囊缩小是临床成功的替代标志物,并且已证明与器械相关。2004 年引入的低通透性 Excluder 覆膜支架(Excluder 低通透性覆膜支架 [ELPE];W. L. Gore & Associates Inc,Flagstaff,Ariz)在早期随访中报告的瘤囊缩小率与其他内支架相似,而原始的 Excluder 则因瘤囊内液体积聚而导致瘤囊生长。本研究的目的是确定在中期至长期随访中这种行为是否持久。
在两个机构中,2004 年 7 月至 2007 年 12 月期间,有 301 名患者接受了 ELPE 的 EVAR。修复后 1 个月通过计算机断层扫描(CT)扫描测量瘤囊大小。1 年以上的随访通过 CT 或超声扫描进行。与基线相比,瘤囊大小变化≥5 毫米被认为有显著意义。使用 χ²和逻辑回归分析评估内漏史与瘤囊行为的关系。
216 名患者(平均年龄 73.6 岁,76%为男性)至少有 1 年的随访影像学资料可供分析。平均随访时间为 2.6 年(范围,1-5 年)。基线时的平均短轴直径为 52mm。在研究期间,瘤囊缩小的患者比例相似:分别为 1 至 5 年的 58%、66%、60%、59%和 63%。随着时间的推移,瘤囊生长的患者比例增加,在 4 年随访时达到 14.8%。4 年时无瘤囊生长的概率为 82.4%。80 名患者(37.7%)在随访期间的某个时间点检测到内漏,4 年时仍有 29.6%(16/54)的残余内漏率;残余的 16 个内漏中有 13 个为 II 型。与瘤囊缩小的患者相比,所有瘤囊生长的患者在研究期间的某个时间点都有内漏(P<.0001)。
ELPE 排除 AAA 后,瘤囊缩小可持续至 5 年随访。仅在当前或先前的内漏存在的情况下观察到瘤囊增大,未观察到疑似淋巴肿形成的病例。